...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Induction chemotherapy in non small cell lung cancer stage IIIa-b and IV and second-line treatment.
【24h】

Induction chemotherapy in non small cell lung cancer stage IIIa-b and IV and second-line treatment.

机译：非小细胞肺癌IIIa-b和IV期及二线治疗的诱导化疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study investigates the treatment management and survival of inoperable advanced non-small cell lung cancer (NSCLC) patients. The objective was to treat all patients with induction chemotherapy and then to stratify them for surgery, radiotherapy, second-line chemotherapy or supportive treatment. Of the 359 patients enrolled in the study, 336 fulfilled the study criteria and were classified as follows: 90 stage IIIa, 135 stage IIIb and 111 stage IV. Histological types included 131 squamous cell, 123 adenocarcinomas, 53 undifferentiated non-small, 15 large cell, 3 adenosquamous, 3 bronchoalveolar and 8 unclassified. For all patients induction therapy involved Cisplatin (CDDP) combined chemotherapy and 84% of the patients were also treated with Vindesine and Epirubicin. The mean number of courses was 4 (minimum 2, maximum 11). The result of induction therapy was 49% complete and partial for at least 8 weeks; with minor response included, the total response rate was 67.6%. Fourteen patients (4.16%) achieved analytically complete response, 151 (45%) partial response and 62 (18.5%) minor response. The second-line treatment implemented was as follows: surgical excision, 22 patients (Group A); radiotherapy, 106 patients (Group B); chemotherapy, 91 patients (Group C) and supportive treatment, 117 patients (Group D). Median survival in months was 72 (range 5-120+), 12 (range 2-118), 15 (range 3-48) and 7 (range 3-120) for Groups A-D respectively. There was a statistically significant difference in survival in Group A patients (p < 0.001) but no difference was observed between Groups B and C. Group D patients had significantly lower survival than the other three groups. In conclusion, induction chemotherapy renders a reasonably high response rate in operable NSCLC patients and second-line radiotherapy treatment is not superior to second-line chemotherapy.
机译：本研究调查了无法手术的晚期非小细胞肺癌（NSCLC）患者的治疗管理和生存率。目的是对所有接受诱导化疗的患者进行治疗，然后对他们进行手术，放疗，二线化疗或支持治疗的分层。在该研究的359名患者中，有336名符合研究标准，并被分类如下：90期IIIa期，135期IIIb期和111期IV期。组织学类型包括131个鳞状细胞，123个腺癌，53个未分化的非小细胞，15个大细胞，3个腺鳞癌，3个支气管肺泡和8个未分类。对于所有患者，均采用顺铂（CDDP）联合化疗进行诱导治疗，其中84％的患者也接受了长春地辛和表柔比星治疗。平均课程数为4（最少2个，最多11个）。诱导治疗的结果是49％的完全性和部分性的，持续至少8周。包括轻微回应，总回应率为67.6％。 14名患者（4.16％）达到了分析上的完全缓解，151（45％）部分缓解，62（18.5％）次要缓解。实施的二线治疗方法如下：手术切除22例（A组）;手术切除。放射治疗106例（B组）;化疗91例（C组）和支持治疗117例（D组）。 A-D组的月份中位生存期分别为72（5-120 +），12（2-118），15（3-48）和7（3-120）。 A组患者的生存率具有统计学意义（p <0.001），但B组和C组之间没有观察到差异。D组患者的生存率明显低于其他三组。总之，诱导化疗在可手术的NSCLC患者中具有相当高的缓解率，二线放疗并不优于二线化疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号